Christopher J Jones

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5004126/publications.pdf

Version: 2024-02-01

28 papers 1,733 citations

394421 19 h-index 26 g-index

28 all docs

28 docs citations

times ranked

28

1866 citing authors

#	Article	IF	CITATIONS
1	Telomerase prevents the accelerated cell ageing of Werner syndrome fibroblasts. Nature Genetics, 2000, 24, 16-17.	21.4	315
2	Preferential binding of the xeroderma pigmentosum group A complementing protein to damaged DNA. Biochemistry, 1993, 32, 12096-12104.	2.5	301
3	Posttranslational Modifications of p53 in Replicative Senescence Overlapping but Distinct from Those Induced by DNA Damage. Molecular and Cellular Biology, 2000, 20, 2803-2808.	2.3	187
4	Sleep deprivation potentiates HPA axis stress reactivity in healthy adults Health Psychology, 2014, 33, 1430-1434.	1.6	171
5	Prevention of Accelerated Cell Aging in Werner Syndrome Using a p38 Mitogen-Activated Protein Kinase Inhibitor. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2005, 60, 1386-1393.	3.6	84
6	A Titrate-to-Goal Study of Switching Patients Uncontrolled on Antihypertensive Monotherapy to Fixed-Dose Combinations of Amlodipine and Olmesartan Medoxomil $\hat{A}\pm$ Hydrochlorothiazide. Journal of Clinical Hypertension, 2011, 13, 404-412.	2.0	73
7	Telomere-based proliferative lifespan barriers in Werner-syndrome fibroblasts involve both p53-dependent and p53-independent mechanisms. Journal of Cell Science, 2003, 116, 1349-1357.	2.0	55
8	Interactions of the transcription/DNA repair factor TFIIH and XP repair proteins with DNA lesions in a cell-free repair assay. Journal of Molecular Biology, 1998, 281, 211-218.	4.2	54
9	Telomerase activity and telomere length in thyroid neoplasia: biological and clinical implications. Journal of Pathology, 2001, 194, 183-193.	4.5	48
10	Normal telomere erosion rates at the single cell level in Werner syndrome fibroblast cells. Human Molecular Genetics, 2004, 13, 1515-1524.	2.9	47
11	p53-Dependent growth arrest and altered p53-immunoreactivity following metabolic labelling with 32P ortho-phosphate in human fibroblasts. Oncogene, 1999, 18, 3788-3792.	5.9	43
12	Does telomere shortening drive selection forp53 mutation in human cancer?. Molecular Carcinogenesis, 1995, 12, 119-123.	2.7	41
13	An analysis of replicative senescence in dermal fibroblasts derived from chronic leg wounds predicts that telomerase therapy would fail to reverse their disease-specific cellular and proteolytic phenotype. Experimental Cell Research, 2003, 283, 22-35.	2.6	39
14	Fibroblast clones from patients with Hutchinson–Gilford progeria can senesce despite the presence of telomerase. Experimental Gerontology, 2004, 39, 461-467.	2.8	36
15	Characterisation of novel mutations in Cockayne syndrome type A and xeroderma pigmentosum group C subjects. Journal of Human Genetics, 2005, 50, 151-154.	2.3	35
16	Tumor-environment biomimetics delay peritoneal metastasis formation by deceiving and redirecting disseminated cancer cells. Biomaterials, 2015, 54, 148-157.	11.4	34
17	Repair of damaged DNA by extracts from a xeroderma pigmentosum complementation group A revertant and expression of a protein absent in its parental cell line. Nucleic Acids Research, 1992, 20, 991-995.	14.5	31
18	Dissociation of Telomere Dynamics from Telomerase Activity in Human Thyroid Cancer Cells. Experimental Cell Research, 1998, 240, 333-339.	2.6	28

#	Article	IF	CITATIONS
19	Telomerase activity is a biomarker for high grade malignant peripheral nerve sheath tumors in neurofibromatosis type 1 individuals. Genes Chromosomes and Cancer, 2008, 47, 238-246.	2.8	23
20	Telomere erosion triggers growth arrest but not cell death in human cancer cells retaining wild-type p53: implications for antitelomerase therapy. Oncogene, 2004, 23, 4136-4145.	5.9	18
21	The Tumour Suppressor Gene p53 as a Regulator of Proliferative Life-Span and Tumour Progression. NeuroSignals, 1996, 5, 139-153.	0.9	16
22	Nucleotide Excision Repair of DNA by Mammalian Cell Extracts and Purified Proteins. Cold Spring Harbor Symposia on Quantitative Biology, 1993, 58, 625-632.	1.1	16
23	Telomerase and cellular lifespan: Ending the debate?. Nature Biotechnology, 1998, 16, 701-702.	17.5	15
24	Mutation and expression of the XPA gene in revertants and hybrids of a xeroderma pigmentosum cell line. Somatic Cell and Molecular Genetics, 1994, 20, 327-337.	0.7	10
25	Is TFIIH an activator of the p53-mediated G1/S checkpoint?. Trends in Genetics, 1995, 11 , $165-166$.	6.7	9
26	Analysis of cells harboring a putative DNA repair gene reveals a lack of evidence for a second independent xeroderma pigmentosum group A correcting gene. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis, 1994, 324, 159-164.	1.1	4
27	The Genome Stability Network. Mutagenesis, 2005, 20, 151-151.	2.6	0
28	Translating cancer genetics into mechanism-based drug discovery. Toxicology, 2006, 226, 15-16.	4.2	0